Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS G12V TCR-T cells Clone 1
- Development stage
- Preclinical
- Lead developer
- Shanghai Xinpu BioTechnology
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KRAS G12V TCR-T cells Clone 1 is an autologous T-cell receptor-engineered T-cell (TCR-T) therapy targeting the KRAS G12V neoantigen presented by the HLA-A1101 molecule. Developed by Shanghai Xinpu BioTechnology, the TCR was isolated from a patient with non-small cell lung cancer (NSCLC) who achieved a partial response following treatment with a KRAS G12V mRNA vaccine. Clone 1 was selected as the lead candidate based on its high functional avidity, specific recognition of the mutant peptide (VVGAVGVGK) without reactivity to wild-type KRAS, and robust antitumor activity in pancreatic cancer xenograft models. Preliminary studies indicate that these TCR-T cells persist in vivo for 10-17 days and distribute to lymphoid organs, blood, and tumor sites.
- Other names
- KRAS G12V/HLA-A1101-specific TCR-T cells
02
Targets
KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)
Beyond the preview
Go deeper on KRAS G12V TCR-T cells Clone 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS G12V TCR-T cells Clone 1.